See what’s new.
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma
This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.
CITI Program Begins Innovative Licensing Partnership with Duke University
Just ASK™ is copyrighted course material developed by Dr. Nadine Barrett (formerly Family Medicine and Community Health, SOM) on how to increase equity and diversity in clinical trials.
Duke is Inventive: A Century of Innovation at Duke University
A new Centennial physical and digital exhibit from OTC collects innovations, inventors, and companies spinning out of Duke University.
Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.
New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.
Clinetic Announces Series A Funding Round Led by Sopris Capital
Clinetic is a medical records Duke start-up founded on technology developed by a team at the Duke Institute for Health Innovation
Newly Identified Lipid in Breast Milk Might Reduce Cerebral Palsy in Infants
Tellus Therapeutics, a neonatal white matter injury therapeutics start-up, was co-founded by Dr. Eric Brenner (Pediatrics, SOM)
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301
Evecxia Therapeutics is a Duke University start-up, founded by inventors Drs. Jacob Jacobsen and Marc Caron (Cell Biology, SOM) around their serotonin synthesis amplification therapeutic technology for mental health applications.
Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy
Istari Oncology was founded by Drs. Darell Bigner and Matthias Gromeier (Neurosurgery, SOM).